Soluble epoxide hydrolase plays an essential role in angiotensin II-induced cardiac hypertrophy

Proceedings of the National Academy of Sciences of the United States of America

Volumn 106, Issue 2, 2009, Pages 564-569

  Ai, Ding ^a,b   Pang, Wei ^a   Li, Nan ^a   Xu, Ming ^a   Jones, Paul D ^b,c   Yang, Jun ^b   Zhang, Youyi ^a   Chiamvimonvat, Nipavan ^d   Shyy, John Y J ^e   Hammock, Bruce D ^b   Zhu, Yi ^a  

^a PEKING UNIVERSITY   (China)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c INTERNATIONAL FLAVORS AND FRAGRANCES INC   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Activator protein 1; Cardiomyocyte; Epoxyeicosatrienoic acid

Indexed keywords

1 (1 METHANESULFONYLPIPERIDIN 4 YL) 3 (4 TRIFLUOROMETHOXYPHENYL)UREA; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II; ATRIAL NATRIURETIC FACTOR; BIOLOGICAL MARKER; EPOXIDE HYDROLASE; HYDROLASE INHIBITOR; LOSARTAN; MYOSIN HEAVY CHAIN BETA; NORADRENALIN; UNCLASSIFIED DRUG;

ADENOVIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ISOLATION; CELL SIZE; CONTROLLED STUDY; DISEASE COURSE; DISEASE MARKER; ECHOCARDIOGRAPHY; ENZYME ACTIVITY; ESSENTIAL HYPERTENSION; EXERCISE; GENE OVEREXPRESSION; HEART; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE CELL; HEART PROTECTION; IN VITRO STUDY; KNOCKOUT MOUSE; MALE; MOUSE; NEWBORN; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; RECEPTOR BLOCKING; TISSUE LEVEL; UPREGULATION; WISTAR RAT;

ANGIOTENSIN II; ANIMALS; ANIMALS, NEWBORN; CARDIOMEGALY; EPOXIDE HYDROLASES; MICE; MICE, KNOCKOUT; MYOCARDIUM; MYOCYTES, CARDIAC; RATS; UP-REGULATION;

ADENOVIRIDAE; MUS; RATTUS; RATTUS NORVEGICUS; RODENTIA;

EID: 58849115391     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0811022106     Document Type: Article

References (49)

1. Katz AM (1995) The cardiomyopathy of overload: an unnatural growth response. Eur Heart J 16(Suppl O):110-114.
2. Olson EN, Schneider MD (2003) Sizing up the heart: development redux in disease. Genes Dev 17(16):1937-1956.
3. Morkin E (1993) Regulation of myosin heavy chain genes in the heart. Circulation 87(5):1451-1460.
4. de Bold AJ, et al. (2001) The physiological and pathophysiological modulation of the endocrine function of the heart. Can J Physiol Pharmacol 79(8):705-714.
5. Mann DL (2004) Heart Failure: A Companion to Braunwald's Heart Disease (Saunders, Philadelphia), pp 10-40.
6. Spector AA, Fang X, Snyder GD, Weintraub NL (2004) Epoxyeicosatrienoic acids (EETs): metabolism and biochemical function. Prog Lipid Res 43(1):55-90.
7. Yu Z, et al. (2000) Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids. Circ Res 87(11):992-998.
8. Zeldin DC, et al. (1996) Biochemical characterization of the human liver cytochrome P450 arachidonic acid epoxygenase pathway. Arch Biochem Biophys 330(1):87-96.
9. Imig JD, Zhao X, Capdevila JH, Morisseau C, Hammock BD (2002) Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension. Hypertension 39(2 Pt 2):690-694.
10. Xu D, et al. (2006) Prevention and reversal of cardiac hypertrophy by soluble epoxide hydrolase inhibitors. Proc Natl Acad Sci USA 103(49):18733-18738.
11. Ai D, et al. (2007) Angiotensin II up-regulates soluble epoxide hydrolase in vascular endothelium in vitro and in vivo. Proc Natl Acad Sci USA 104(21):9018-9023.
12. Luria A, et al. (2007) Compensatory mechanism for homeostatic blood pressure regulation in Ephx2 gene-disrupted mice. J Biol Chem 282(5):2891-2898.
13. Loch D, Hoey A, Morisseau C, Hammock BO, Brown L (2007) Prevention of hypertension in DOCA-salt rats by an inhibitor of soluble epoxide hydrolase. Cell Biochem Biophys 47(1):87-98.
14. Imig JD, et al. (2005) A norally active epoxide hydrolase inhibitor lowers blood pressure and provides renal protection in salt-sensitive hypertension. Hypertension 46(4):975-981.
15. Aoki H, Richmond M, Izumo S, Sadoshima J (2000) Specific role of the extracellular signal-regulated kinase pathway in angiotensin II-induced cardiac hypertrophy in vitro. Biochem J 347(Pt 1):275-284.
16. Shih NL, et al. (2001) Reactive oxygen species modulate angiotensin II-induced beta-myosin heavy chain gene expression via Ras/Raf/extracellular signal-regulated kinase pathway in neonatal rat cardiomyocytes. Biochem Biophys Res Commun 283(1):143-148.
17. Bao W, et al. (2007) Effects of p38 MAPK Inhibitor on angiotensin II-dependent hypertension, organ damage, and superoxide anion production. J Cardiovasc Pharmacol 49(6):362-368.
18. Wenzel S, Taimor G, Piper HM, Schluter KD (2001) Redox-sensitive intermediates mediate angiotensin II-induced p38 MAP kinase activation, AP-1 binding activity, and TGF-beta expression in adult ventricular cardiomyocytes. FASEB J 15(12):2291-2293.
19. Kudoh S, et al. (1997) Angiotensin II stimulates c-Jun NH2-terminal kinase in cultured cardiac myocytes of neonatal rats. Circ Res 80(1):139-146.
20. Yano M, Kim S, Izumi Y, Yamanaka S, Iwao H (1998) Differential activation of cardiac c-jun amino-terminal kinase and extracellular signal-regulated kinase in angiotensin II-mediated hypertension. Circ Res 83(7):752-760.
21. Izumi Y, et al. (2000) Important role of angiotensin II-mediated c-Jun NH(2)-terminal kinase activation in cardiac hypertrophy in hypertensive rats. Hypertension 36(4):511-516.
22. Taimor G, Rakow A, Piper HM (2001) Transcription activator protein 1 (AP-1) mediates NO-induced apoptosis of adult cardiomyocytes. FASEB J 15(13):2518-2520.
23. Tu VC, Bahl JJ, Chen QM (2003) Distinct roles of p42/p44(ERK) and p38 MAPK in oxidant-induced AP-1 activation and cardiomyocyte hypertrophy. Cardiovasc Toxicol 3(2):119-133.
24. Fiebeler A, et al. (2001) Mineralocorticoid receptor affects AP-1 and nuclear factor-kappab activation in angiotensin II-induced cardiac injury. Hypertension 37(2 Pt 2):787-793.
25. Tanaka H, et al. (2008) Transcriptional regulation of the human soluble epoxide hydrolase gene EPHX2. Biochim Biophys Acta 1779(1):17-27.
26. Yamada S, et al. (2006) Protection conferred by myocardial ATP-sensitive K+ channels in pressure overload-induced congestive heart failure revealed in KCNJ11 Kir6.2-null mutant. J Physiol 577(Pt 3):1053-1065.
27. Hanley PJ, Daut J (2005) K(ATP) channels and preconditioning: a re-examination of the role of mitochondrial K(ATP) channels and an overview of alternative mechanisms. J Mol Cell Cardiol 39(1):17-50.
28. Xu W, et al. (2002) Cytoprotective role of Ca2+- activated K+ channels in the cardiac inner mitochondrial membrane. Science 298(5595):1029-1033.
29. Gross GJ, Peart JN (2003) KATP channels and myocardial preconditioning: an update. Am J Physiol Heart Circ Physiol 285(3):H921-930.
30. Gross GJ, Fryer RM (1999) Sarcolemmal versus mitochondrial ATP-sensitive K+ channels and myocardial preconditioning. Circ Res 84(9):973-979.
31. O'Rourke B (2004) Evidence for mitochondrial K+ channels and their role in cardioprotection. Circ Res 94(4):420-432.
32. Siemen D, Loupatatzis C, Borecky J, Gulbins E, Lang F (1999) Ca2+-activated K channel of the BK-type in the inner mitochondrial membrane of a human glioma cell line. Biochem Biophys Res Commun 257(2):549-554.
33. Tsuchiya K, et al. (1997) Functional compartmentalization of ATP is involved in angiotensin II-mediated closure of cardiac ATP-sensitive K+ channels. Circulation 96(9):3129-3135.
34. Liu Y, Sato T, O'Rourke B, Marban E (1998) Mitochondrial ATP-dependent potassium channels: Novel effectors of cardioprotection? Circulation 97(24):2463-2469.
35. Seubert JM, et al. (2006) Role of soluble epoxide hydrolase in postischemic recovery of heart contractile function. Circ Res 99(4):442-450.
36. Morisseau C, et al. (2002) Structural refinement of inhibitors of urea-based soluble epoxide hydrolases. Biochem Pharmacol 63(9):1599-1608.
37. Morisseau C, et al. (1999) Potent urea and carbamate inhibitors of soluble epoxide hydrolases. Proc Natl Acad Sci USA 96(16):8849-8854.
38. McElroy NR, Jurs PC, Morisseau C, Hammock BD (2003) QSAR and classification of murine and human soluble epoxide hydrolase inhibition by urea-like compounds. J Med Chem 46(6):1066-1080.
39. Kim IH, Morisseau C, Watanabe T, Hammock BD (2004) Design, synthesis, and biological activity of 1,3-disubstituted ureas as potent inhibitors of the soluble epoxide hydrolase of increased water solubility. J Med Chem 47(8):2110-2122.
40. Jones PD, Tsai HJ, Do ZN, Morisseau C, Hammock BD (2006) Synthesis and SAR of conformationally restricted inhibitors of soluble epoxide hydrolase. Bioorg Med Chem Lett 16(19):5212-5216.
41. Chiamvimonvat N, Ho CM, Tsai HJ, Hammock BD (2007) The soluble epoxide hydrolase as a pharmaceutical target for hypertension. J Cardiovasc Pharmacol 50(3):225-237.
42. McMullen JR, et al. (2007) Protective effects of exercise and phosphoinositide 3-kinase(p110alpha) signaling in dilated and hypertrophic cardiomyopathy. Proc Natl Acad Sci USA 104(2):612-617.
43. Luo J, et al. (2005) Class IA phosphoinositide 3-kinase regulates heart size and physiological cardiac hypertrophy. Mol Cell Biol 25(21):9491-9502.
44. Harada K, et al. (1998) Pressure overload induces cardiac hypertrophy in angiotensin II type 1A receptor knockout mice. Circulation 97:1952-1959.
45. Byrne JA, et al. (2003) Contrasting roles of NADPH oxidase isoforms in pressure-overload versus angiotensin II-induced cardiac hypertrophy. Circ Res 93:802.
46. Rapacciuolo A, et al. (2001) Important role of endogenous norepinephrine and epinephrine in the development of in vivo pressure-overload cardiac hypertrophy. J Am Coll Cardiol 38(3):876-882.
47. Liao Y, et al. (2003) Activation of adenosine A1 receptor attenuates cardiac hypertrophy and prevents heart failure in murine left ventricular pressure-overload model. Circ Res 93(8):759-766.
48. Taigen T, De Windt LJ, Lim HW, Molkentin JD (2000) Targeted inhibition of calcineurin prevents agonist-induced cardiomyocyte hypertrophy. Proc Natl Acad Sci USA 97(3):1196-1201.
49. Xu Y, et al. (2005) The effects of intracellular Ca2 on cardiac K+ channel expression and activity: novel insights from genetically altered mice. J Physiol 562(Pt 3):745-758.